Electrophysiological Biomarkers in Genetic Epilepsies
| Autor: | Eric D. Marsh, Caren Armstrong |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Neurology Review Epilepsy medicine Humans Pharmacology (medical) Precision Medicine Medical diagnosis Intensive care medicine Pharmacology Brain Diseases business.industry Clinical study design Brain Cognition Precision medicine medicine.disease Clinical trial Neurodevelopmental Disorders Evoked Potentials Visual Biomarker (medicine) Anticonvulsants Neurology (clinical) business Biomarkers |
| Zdroj: | Neurotherapeutics |
| ISSN: | 1878-7479 1933-7213 |
| DOI: | 10.1007/s13311-021-01132-4 |
| Popis: | Precision treatments for epilepsy targeting the underlying genetic diagnoses are becoming a reality. Historically, the goal of epilepsy treatments was to reduce seizure frequency. In the era of precision medicine, however, outcomes such as prevention of epilepsy progression or even improvements in cognitive functions are both aspirational targets for any intervention. Developing methods, both in clinical trial design and in novel endpoints, will be necessary for measuring, not only seizures, but also the other neurodevelopmental outcomes that are predicted to be targeted by precision treatments. Biomarkers that quantitatively measure disease progression or network level changes are needed to allow for unbiased measurements of the effects of any gene-level treatments. Here, we discuss some of the promising electrophysiological biomarkers that may be of use in clinical trials of precision therapies, as well as the difficulties in implementing them. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13311-021-01132-4. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink